AAK1 Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the AP2-associated kinase 1 (AAK1) gene, providing a heterogeneous loss-of-function model free from clonal selection biases. This polyclonal pool is particularly suited for investigating endocytosis, signal transduction, and receptor trafficking within a hepatocyte-derived background.
The host Huh-7 cell line is a human hepatocellular carcinoma (HCC) line established from the liver tumor of a 57-year-old Japanese male. These adherent epithelial cells retain key hepatocyte features and are extensively used to model HCC biology, hepatitis C virus (HCV) infection, and liver-specific receptor internalization pathways. Their robust clathrin-mediated endocytic activity makes Huh-7 an ideal system for studying AAK1-dependent trafficking.
AAK1 encodes a serine/threonine kinase that critically regulates clathrin-mediated endocytosis by phosphorylating the ??2 subunit (AP2M1) of the AP-2 adaptor complex. This phosphorylation event drives cargo recruitment and clathrin coat assembly, enabling efficient internalization of receptors such as EGFR and Notch1. AAK1 functions downstream of clathrin and AP-2, interacting with AP-2 subunits (AP2A2, AP2B1, AP2M1, AP2S1) and the adaptor Numb. By controlling receptor endocytosis, AAK1 modulates downstream pathways including Notch-mediated HES1 transcription, EGFR-dependent MAPK/ERK signaling, and WNT/??-catenin activity, thereby acting as a master switch for plasma membrane receptor availability.
In Huh-7 cells, abrogation of AAK1 expression disrupts clathrin-dependent internalization of growth factor receptors, potentially attenuating oncogenic EGFR and Notch signaling??pathways frequently dysregulated in hepatocellular carcinoma. As HCV entry requires clathrin-mediated endocytosis, this knockout model enables precise dissection of AAK1??s contribution to viral infection and replication. Moreover, the cells serve as a valuable tool for preclinical validation of AAK1 inhibitors being pursued for chronic pain and substance use disorders, offering a non-neuronal platform to assess downstream signaling effects.
Key research applications include mechanistic endocytosis studies, Notch and EGFR signaling investigations, HCV infection and replication assays, drug target validation, and cancer biology. Compatible assays range from Western blotting for AAK1 and phospho-AP2M1, immunofluorescence analyses of clathrin-coated pits and EGFR internalization, flow cytometry-based transferrin uptake measurements, Notch reporter assays, to migration and invasion studies. For further information, please contact Ascent Research.
